Matinas BioPharma Holdings MTNB
NYSE MTNB
$0.19 -0.05 (-20.83%)
At close: Aug 20, 2026 · 4:00 PM EDT

Matinas BioPharma Holdings (MTNB) Receivables (2018 - 2021)

Matinas BioPharma Holdings (MTNB) posted quarterly Receivables of $980000.0 for Q3 2021, up 991.16% quarter-over-quarter from $89813.0 in Q2 2018.

Matinas BioPharma Holdings (MTNB) Receivables (2018 - 2021) Analysis & Trends

Matinas BioPharma Holdings (MTNB) has reported Receivables for 2 consecutive years, with $980000.0 the latest figure, recorded in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn 2.13 Bn
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 6.57 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn 1.93 Bn
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn 160.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 1.06 Bn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn 912.74 Mn
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn 215.33 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn - -
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn 1.09 Bn
10 Matinas BioPharma Holdings 1.19 Mn 375,426.61 - -

Historic Data

Download Data
DateValue
Sep 30, 2021 980,000.00
Jun 30, 2018 89,813.00